SPOTLIGHT -
A note about Drug Watch
Pfizer Stops GLP-1 Obesity Trial Because of High Discontinuation Rates
Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.
Younger People Are Looking to GLP-1 Drugs for Weight Loss
A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.
HHS: Opportunities to Reduce Medicare Part B Spending with Biosimilars Remain
Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Enzyme Replacement Therapy Adzynma Launches with $245,000 Annual Price
Adzynma is a recombinant protein designed to replace the deficient ADAMTS13 enzyme to treat patients with the rare hereditary blood clotting disorder congenital thrombotic thrombocytopenic purpura
FDA Sets Review Date for Zoryve in Atopic Dermatitis
The FDA has set a date of July 07, 2024, for Zorvye 0.15% for adults and children six and up with the chronic skin disease atopic dermatitis.
FDA Issues Warning about Seizure Medications
Regulators have found that medications containing levetiracetam and clobazam have led to drug reaction with eosinophilia and systemic symptoms (DRESS), a rare and severe drug allergy.
